

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Booth Bruce</u> (Last) (First) (Middle) C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, FLOOR 4 (Street) WATERTOWN MA 02472 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Kymera Therapeutics, Inc. [KYMR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/26/2026	
	4. If Amendment, Date of Original Filed (Month/Day/Year) 06/30/2026	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/29/2026		S ⁽¹⁾		5,549 ⁽²⁾	D	\$105.78 ⁽³⁾	2,446,375 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		14,798 ⁽²⁾	D	\$106.63 ⁽⁵⁾	2,431,577 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		19,419 ⁽²⁾	D	\$107.76 ⁽⁶⁾	2,412,158 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		10,848 ⁽²⁾	D	\$108.28 ⁽⁷⁾	2,401,310 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		7,968 ⁽²⁾	D	\$109.75 ⁽⁸⁾	2,393,342 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		7,723 ⁽²⁾	D	\$110.67 ⁽⁹⁾	2,385,619 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		934 ⁽²⁾	D	\$111.2 ⁽¹⁰⁾	2,384,685 ⁽²⁾	I	See footnote ⁽⁴⁾
Common Stock	06/29/2026		S ⁽¹⁾		770 ⁽²⁾	D	\$105.78 ⁽³⁾	471,497 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		2,133 ⁽²⁾	D	\$106.63 ⁽⁵⁾	469,364 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		2,698 ⁽²⁾	D	\$107.76 ⁽⁶⁾	466,666 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		1,498 ⁽²⁾	D	\$108.28 ⁽⁷⁾	465,168 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		1,104 ⁽²⁾	D	\$109.75 ⁽⁸⁾	464,064 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		1,078 ⁽²⁾	D	\$110.67 ⁽⁹⁾	462,986 ⁽²⁾	I	See footnote ⁽¹¹⁾
Common Stock	06/29/2026		S ⁽¹⁾		130 ⁽²⁾	D	\$111.2 ⁽¹⁰⁾	462,856 ⁽²⁾	I	See footnote ⁽¹¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (Month/Day/Year)	5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
- The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.015 to \$106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
- These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.0271 to \$106.96 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$107.03 to \$108.0293 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.0326 to \$109.019 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.034 to \$109.96 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.09 to \$111.08 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.09 to \$111.63 inclusive.
- The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Remarks:

This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged.

/s/ Ommer Chohan, Attorney-in-Fact 07/02/2026
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.